“Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma” has been added to your cart. View cart

Article: Daratumumab news at EHA 2019: promising results in transplant-eligible multiple myeloma patients and a more convenient subcutaneous drug formulation

€3.03

SKU: product-article-17493 Category: General

Description
Reviews (0)

Description

Daratumumab news at EHA 2019: promising results in transplant-eligible multiple myeloma patients and a more convenient subcutaneous drug formulation

Top

Article: Daratumumab news at EHA 2019: promising results in transplant-eligible multiple myeloma patients and a more convenient subcutaneous drug formulation

Description

Reviews

Related products

1 year subscription print edition of the Belgian Journal of Hematology (BJH)

Article: Highlights in melanoma

Article: Calendar of events

Article: Highlights in squamous cell carcinoma of the head and neck